Literature DB >> 28947473

Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.

Shawn H MacVane1,2, Ruchi Pandey3, Lisa L Steed4, Barry N Kreiswirth3, Liang Chen3.   

Abstract

Ceftolozane-tazobactam is a cephalosporin-β-lactamase inhibitor combination that exhibits potent in vitro activity against Pseudomonas aeruginosa, including strains that are resistant to other β-lactams. The emergence of ceftolozane-tazobactam resistance among clinical isolates of P. aeruginosa has rarely been described. Here we characterized ceftolozane-tazobactam-resistant P. aeruginosa strains recovered from a patient who was treated with this agent for 6 weeks for a recurrent wound infection. The results showed that the resistance was mediated by a single AmpC structural mutation.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  AmpC; G183D; Pseudomonas aeruginosa; ceftolozane-tazobactam

Mesh：

Substances：

Year:  2017        PMID： 28947473      PMCID： PMC5700322          DOI： 10.1128/AAC.01183-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Multilocus sequence typing of total-genome-sequenced bacteria.

Authors:  Mette V Larsen; Salvatore Cosentino; Simon Rasmussen; Carsten Friis; Henrik Hasman; Rasmus Lykke Marvig; Lars Jelsbak; Thomas Sicheritz-Pontén; David W Ussery; Frank M Aarestrup; Ole Lund
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

2.  Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC.

Authors:  Sushmita D Lahiri; Grant K Walkup; James D Whiteaker; Tiffany Palmer; Kathy McCormack; M Angela Tanudra; Tory J Nash; Jason Thresher; Michele R Johnstone; Laurie Hajec; Stephania Livchak; Robert E McLaughlin; Richard A Alm
Journal:  J Antimicrob Chemother       Date:  2015-02-01       Impact factor: 5.790

3.  Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.

Authors:  Gabriel Cabot; Sebastian Bruchmann; Xavier Mulet; Laura Zamorano; Bartolomé Moyà; Carlos Juan; Susanne Haussler; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

4.  Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.

Authors:  Dee Shortridge; Mariana Castanheira; Michael A Pfaller; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

5.  Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria.

Authors:  Joshua T Thaden; Lawrence P Park; Stacey A Maskarinec; Felicia Ruffin; Vance G Fowler; David van Duin
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

6.  Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.

Authors:  Ryan K Shields; Liang Chen; Shaoji Cheng; Kalyan D Chavda; Ellen G Press; Avin Snyder; Ruchi Pandey; Yohei Doi; Barry N Kreiswirth; M Hong Nguyen; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

Review 7.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  David van Duin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2016-04-20       Impact factor: 9.079

8.  Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.

Authors:  Ghady Haidar; Nathan J Philips; Ryan K Shields; Daniel Snyder; Shaoji Cheng; Brian A Potoski; Yohei Doi; Binghua Hao; Ellen G Press; Vaughn S Cooper; Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2017-07-01       Impact factor: 9.079

9.  BIGSdb: Scalable analysis of bacterial genome variation at the population level.

Authors:  Keith A Jolley; Martin C J Maiden
Journal:  BMC Bioinformatics       Date:  2010-12-10       Impact factor: 3.169
  9 in total
  25 in total

1.  A Case-Control Study of Real-Life Experience with Ceftolozane-Tazobactam in Patients with Hematologic Malignancy and Pseudomonas aeruginosa Infection.

Authors:  Ana Fernández-Cruz; Natalia Alba; María Auxiliadora Semiglia-Chong; Belén Padilla; Gabriela Rodríguez-Macías; Mi Kwon; Emilia Cercenado; Esther Chamorro-de-Vega; Marina Machado; Laura Pérez-Lago; Darío García de Viedma; José Luis Díez Martín; Patricia Muñoz
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 2.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

3.  A Standard Numbering Scheme for Class C β-Lactamases.

Authors:  Andrew R Mack; Melissa D Barnes; Magdalena A Taracila; Andrea M Hujer; Kristine M Hujer; Gabriel Cabot; Michael Feldgarden; Daniel H Haft; William Klimke; Focco van den Akker; Alejandro J Vila; Andrea Smania; Shozeb Haider; Krisztina M Papp-Wallace; Patricia A Bradford; Gian Maria Rossolini; Jean-Denis Docquier; Jean-Marie Frère; Moreno Galleni; Nancy D Hanson; Antonio Oliver; Patrick Plésiat; Laurent Poirel; Patrice Nordmann; Timothy G Palzkill; George A Jacoby; Karen Bush; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  A 2.5-years within-patient evolution of a Pseudomonas aeruginosa with in vivo acquisition of ceftolozane-tazobactam and ceftazidime-avibactam resistance upon treatment.

Authors:  Thibaud Boulant; Agnès B Jousset; Rémy A Bonnin; Aurélie Barrail-Tran; Adrien Borgel; Saoussen Oueslati; Thierry Naas; Laurent Dortet
Journal:  Antimicrob Agents Chemother       Date:  2019-10-21       Impact factor: 5.191

5.  Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients.

Authors:  Morgan Hakki; James S Lewis
Journal:  Infection       Date:  2018-02-19       Impact factor: 3.553

6.  Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Adam L Bailey; Tom Armstrong; Hari-Prakash Dwivedi; Gerald A Denys; Janet Hindler; Shelley Campeau; Maria Traczewski; Romney Humphries; C A Burnham
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

7.  Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Krisztina M Papp-Wallace; Elise T Zeiser; Scott A Becka; Steven Park; Brigid M Wilson; Marisa L Winkler; Roshan D'Souza; Indresh Singh; Granger Sutton; Derrick E Fouts; Liang Chen; Barry N Kreiswirth; Evelyn J Ellis-Grosse; George L Drusano; David S Perlin; Robert A Bonomo
Journal:  J Infect Dis       Date:  2019-07-19       Impact factor: 5.226

8.  Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study.

Authors:  Damien Fournier; Romain Carrière; Maxime Bour; Emilie Grisot; Pauline Triponney; Cédric Muller; Jérôme Lemoine; Katy Jeannot; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

Review 9.  The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.

Authors:  Krisztina M Papp-Wallace
Journal:  Expert Opin Pharmacother       Date:  2019-09-09       Impact factor: 3.889

10.  Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.

Authors:  Mazen A Sid Ahmed; Hamad Abdel Hadi; Abubaker A I Hassan; Sulieman Abu Jarir; Muna A Al-Maslamani; Nahla Omer Eltai; Khalid M Dousa; Andrea M Hujer; Ali A Sultan; Bo Soderquist; Robert A Bonomo; Emad Bashir Ibrahim; Jana Jass; Ali S Omrani
Journal:  J Antimicrob Chemother       Date:  2019-12-01       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.